MTOR and breast cancer: One example is everolimus (RAD001), an oral inhibitor of mammalian target of rapamycin acting downstream of the PI3K/AKT pathway, which was shown to have effective inhibitory effects on cancer stem cells in vitro and in vivo, and combination treatment with RAD001 and docetaxel or trastuzumab has been reported to be effective in refractory metastatic BC [81].